|
JP4469026B2
(ja)
*
|
1996-10-31 |
2010-05-26 |
ヒューマン ジノーム サイエンシーズ，インコーポレイテッド |
Ｓｔｒｅｐｔｏｃｏｃｃｕｓ ｐｎｅｕｍｏｎｉａｅの抗原およびワクチン
|
|
US6676943B1
(en)
|
1997-04-24 |
2004-01-13 |
Regents Of The University Of Minnesota |
Human complement C3-degrading protein from Streptococcus pneumoniae
|
|
US6800744B1
(en)
*
|
1997-07-02 |
2004-10-05 |
Genome Therapeutics Corporation |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
|
US7098023B1
(en)
|
1997-07-02 |
2006-08-29 |
Sanofi Pasteur Limited |
Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
|
|
ES2540281T3
(es)
|
1998-02-20 |
2015-07-09 |
Id Biomedical Corporation Of Quebec |
Antígenos de estreptococos del grupo B
|
|
DE69942176D1
(de)
*
|
1998-04-07 |
2010-05-06 |
Medimmune Llc |
Choline-bindende proteine derivate aus pneumokoken als impfstoff
|
|
WO2000005378A2
(en)
|
1998-07-22 |
2000-02-03 |
Id-Lelystad Instituut Voor Dierhouderij En Diergezondheid B.V. |
Streptococcus suis vaccines and diagnostic tests
|
|
EP1801218A3
(en)
*
|
1998-07-27 |
2007-10-10 |
Sanofi Pasteur Limited |
Nucleic acids and proteins from streptococcus pneumoniae
|
|
US20030134407A1
(en)
|
1998-07-27 |
2003-07-17 |
Le Page Richard William Falla |
Nucleic acids and proteins from Streptococcus pneumoniae
|
|
EP1950302B1
(en)
|
1998-12-23 |
2012-12-05 |
ID Biomedical Corporation of Quebec |
Streptococcus antigens
|
|
US7128918B1
(en)
*
|
1998-12-23 |
2006-10-31 |
Id Biomedical Corporation |
Streptococcus antigens
|
|
ES2400280T3
(es)
*
|
1998-12-23 |
2013-04-08 |
Id Biomedical Corporation Of Quebec |
Antígenos de estreptococos
|
|
ES2275499T3
(es)
*
|
1999-03-19 |
2007-06-16 |
Glaxosmithkline Biologicals S.A. |
Vacuna contra streptococcus pneumoniae.
|
|
US6887480B1
(en)
*
|
1999-06-10 |
2005-05-03 |
Medimmune, Inc. |
Streptococcus pneumoniae proteins and vaccines
|
|
AU2001269833A1
(en)
*
|
2000-06-14 |
2001-12-24 |
Cytovax Biotechnologies, Inc. |
Use of coiled-coil structural scaffold to generate structure-specific peptides
|
|
US7074415B2
(en)
*
|
2000-06-20 |
2006-07-11 |
Id Biomedical Corporation |
Streptococcus antigens
|
|
AU2001270381B2
(en)
*
|
2000-06-20 |
2007-05-24 |
Id Biomedical Corporation |
Streptococcus antigens
|
|
GB0022742D0
(en)
*
|
2000-09-15 |
2000-11-01 |
Smithkline Beecham Biolog |
Vaccine
|
|
WO2002061070A2
(en)
|
2001-02-02 |
2002-08-08 |
Id-Lelystad, Instituut Voor Dierhouderij En Diergezondheid B.V. |
Environmentally regulated genes, involved in the virulence of streptococcus suis
|
|
EP1456231A2
(en)
*
|
2001-12-20 |
2004-09-15 |
Shire Biochem Inc. |
Streptococcus antigens
|
|
US8229903B2
(en)
*
|
2002-12-19 |
2012-07-24 |
International Business Machines Corporation |
Suggesting data interpretations and patterns for updating policy documents
|
|
US8398983B2
(en)
|
2005-06-27 |
2013-03-19 |
Glaxosmithkline Biologicals, S.A. |
Immunogenic composition
|
|
EP1754717A1
(en)
|
2005-08-19 |
2007-02-21 |
Université de Lausanne |
Antigenic peptides and their use
|
|
TWI457133B
(zh)
|
2005-12-13 |
2014-10-21 |
Glaxosmithkline Biolog Sa |
新穎組合物
|
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
PL1973564T3
(pl)
|
2005-12-22 |
2017-04-28 |
Glaxosmithkline Biologicals S.A. |
Szczepionki zawierające koniugaty polisacharydu otoczkowego streptococcus pneumoniae
|
|
US8945582B2
(en)
|
2006-09-07 |
2015-02-03 |
Glaxosmithkline Biologicals S.A. |
Vaccine
|
|
CA2683748C
(en)
|
2007-04-13 |
2016-02-16 |
The Board Of Regents Of The University Of Oklahoma |
Mutants of cholesterol-dependent cytolysins and uses thereof
|
|
BRPI0810778A2
(pt)
|
2007-05-02 |
2011-09-13 |
Glaxosmithkline Biolog Sa |
kit, vacina combinada, e, métodos de diminuição da interferência de vizinhança de crm sobre um antìgeno sensìvel em um esquema de imunização primária de uma vacina, e de diminuição da interferência de vizinhança sobre um antìgeno sensìvel, e, uso de conjugados de sacarìdeo
|
|
SI2167121T1
(sl)
|
2007-06-26 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
|
|
BRPI0814127A2
(pt)
|
2007-07-23 |
2015-02-03 |
Sanofi Pasteur Ltd |
Polipeptídeos imunegênicos e anticorpos monoclonais
|
|
US20160228500A9
(en)
*
|
2007-07-23 |
2016-08-11 |
Martina Ochs |
Immunogenic Polypeptides and Monoclonal Antibodies
|
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
|
EP2023143A1
(en)
*
|
2007-08-06 |
2009-02-11 |
Boehringer Ingelheim Vetmedica Gmbh |
Immunogenic streptococcus proteins
|
|
PT2268618E
(pt)
|
2008-03-03 |
2015-10-12 |
Novartis Ag |
Compostos e composições moduladores da actividade tlr
|
|
SI2271360T1
(sl)
|
2008-04-16 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo
|
|
EP2349209A2
(en)
|
2008-09-26 |
2011-08-03 |
Nanobio Corporation |
Nanoemulsion therapeutic compositions and methods of using the same
|
|
EP3017826A1
(en)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
|
|
AU2010243285B2
(en)
|
2009-04-30 |
2013-06-06 |
Coley Pharmaceutical Group, Inc. |
Pneumococcal vaccine and uses thereof
|
|
WO2010132833A1
(en)
|
2009-05-14 |
2010-11-18 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
|
CA2765112A1
(en)
|
2009-06-10 |
2010-12-16 |
Novartis Ag |
Benzonaphthyridine-containing vaccines
|
|
JO3257B1
(ar)
|
2009-09-02 |
2018-09-16 |
Novartis Ag |
مركبات وتركيبات كمعدلات لفاعلية tlr
|
|
ES2443952T3
(es)
|
2009-09-02 |
2014-02-21 |
Novartis Ag |
Composiciones inmunógenas que incluyen moduladores de la actividad de TLR
|
|
PE20161551A1
(es)
|
2009-09-03 |
2017-01-18 |
Pfizer Vaccines Llc |
Vacuna de pcsk9
|
|
CN102695523A
(zh)
|
2009-09-10 |
2012-09-26 |
诺华有限公司 |
针对呼吸道疾病的组合疫苗
|
|
WO2011057148A1
(en)
|
2009-11-05 |
2011-05-12 |
Irm Llc |
Compounds and compositions as tlr-7 activity modulators
|
|
SG10201501980SA
(en)
|
2009-12-15 |
2015-05-28 |
Novartis Ag |
Homogeneous suspension of immunopotentiating compounds and uses thereof
|
|
CN102802664B
(zh)
*
|
2009-12-22 |
2017-04-05 |
赛诺菲巴斯德有限公司 |
免疫原性组合物
|
|
US9649372B2
(en)
|
2009-12-22 |
2017-05-16 |
Sanofi Pasteur Limited |
Immunogenic compositions and related methods
|
|
GB201003924D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Immunogenic composition
|
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
GB201003920D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Method of treatment
|
|
AU2011232421B2
(en)
|
2010-03-23 |
2015-08-13 |
Novartis Ag |
Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
|
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
|
KR20140009281A
(ko)
|
2010-12-03 |
2014-01-22 |
사노피 파스퇴르 리미티드 / 사노피 파스퇴르 리미떼 |
스트렙토코커스 뉴모니애에 대한 면역화를 위한 조성물
|
|
US20140004142A1
(en)
|
2011-03-02 |
2014-01-02 |
Pfizer Inc. |
Pcsk9 vaccine
|
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
|
WO2012156391A1
(en)
*
|
2011-05-17 |
2012-11-22 |
Glaxosmithkline Biologicals S.A. |
Vaccine against streptococcus pneumoniae
|
|
JP2015510872A
(ja)
|
2012-03-07 |
2015-04-13 |
ノバルティス アーゲー |
Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
|
|
JP6411378B2
(ja)
|
2013-02-01 |
2018-10-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Ｔｏｌｌ様受容体アゴニストを含む免疫学的組成物の皮内送達
|
|
JP6494527B2
(ja)
|
2013-02-07 |
2019-04-03 |
ザ チルドレンズ メディカル センター コーポレーション |
肺炎球菌のコロニー形成および／または疾患からの保護を提供するタンパク質抗原
|
|
CN120718167A
(zh)
|
2014-01-21 |
2025-09-30 |
辉瑞大药厂 |
肺炎链球菌荚膜多糖及其缀合物
|
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
IL312327B2
(en)
|
2014-01-21 |
2026-02-01 |
Pfizer |
Immunogenic preparations comprising conjugated capsular saccharide antigens and their uses
|
|
BR112016016580B1
(pt)
|
2014-01-21 |
2024-01-09 |
Pfizer Inc |
Processo para a preparação de um conjugado imunogênico, conjugado imunogênico, composição imunogênica, e vacina
|
|
EP3104886B1
(en)
|
2014-02-14 |
2018-10-17 |
Pfizer Inc |
Immunogenic glycoprotein conjugates
|
|
AU2015349787B2
(en)
|
2014-11-21 |
2021-07-29 |
The Board Of Regents Of The University Of Oklahoma |
Pneumolysin mutants and methods of use thereof
|
|
CN107427568B
(zh)
|
2015-01-15 |
2021-12-14 |
辉瑞公司 |
用于肺炎球菌疫苗中的免疫原性组合物
|
|
CN108367063A
(zh)
|
2015-07-21 |
2018-08-03 |
辉瑞公司 |
包含缀合的荚膜糖抗原的免疫原性组合物及其试剂盒和用途
|
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
|
JP6884145B2
(ja)
|
2015-11-20 |
2021-06-09 |
ファイザー・インク |
肺炎連鎖球菌ワクチンにおいて用いるための免疫原性組成物
|
|
GB201610599D0
(en)
|
2016-06-17 |
2016-08-03 |
Glaxosmithkline Biologicals Sa |
Immunogenic Composition
|
|
US11413344B2
(en)
|
2017-01-20 |
2022-08-16 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
|
GB201711635D0
(en)
|
2017-07-19 |
2017-08-30 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
|
ES2985591T3
(es)
|
2018-02-12 |
2024-11-06 |
Inimmune Corp |
Ligandos de receptores tipo Toll
|
|
WO2020016322A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
CA3120922A1
(en)
|
2018-12-12 |
2020-06-18 |
Pfizer Inc. |
Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
|
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
|
CA3136278A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
|
BR112022001654A2
(pt)
|
2019-07-31 |
2022-07-12 |
Sanofi Pasteur Inc |
Composições conjugadas de proteinas de polissacarídeos pneumocócicos multivalentes e métodos de utilização dos mesmos
|
|
CA3159573A1
(en)
|
2019-11-01 |
2021-05-06 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
CA3171864A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
|
NZ790372A
(en)
|
2020-02-23 |
2026-01-30 |
Pfizer |
Escherichia coli compositions and methods thereof
|
|
JP2023546446A
(ja)
|
2020-10-22 |
2023-11-02 |
ファイザー・インク |
細菌多糖を精製する方法
|
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
|
US12138302B2
(en)
|
2020-10-27 |
2024-11-12 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
|
KR20230098825A
(ko)
|
2020-11-04 |
2023-07-04 |
엘리고 바이오사이언스 |
씨. 아크네스 개체군에게 dna 페이로드의 원위치 전달을 위한 파지-유래 입자
|
|
KR20230097160A
(ko)
|
2020-11-04 |
2023-06-30 |
화이자 인코포레이티드 |
폐렴구균 백신에 사용하기 위한 면역원성 조성물
|
|
US12357681B2
(en)
|
2020-12-23 |
2025-07-15 |
Pfizer Inc. |
E. coli FimH mutants and uses thereof
|
|
CA3218544A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
EP4346893A2
(en)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
MX2023013434A
(es)
|
2021-05-28 |
2023-12-12 |
Pfizer |
Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados y sus usos.
|
|
CA3247998A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions based on conjugated capsular saccharidic antigens and their uses
|
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
|
CN119317445A
(zh)
|
2022-05-11 |
2025-01-14 |
辉瑞公司 |
用于生产含有防腐剂的疫苗制剂的方法
|
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
|
JP2025537898A
(ja)
|
2022-11-22 |
2025-11-20 |
ファイザー・インク |
コンジュゲートさせた莢膜糖類抗原を含む免疫原性組成物およびその使用
|
|
IL321069A
(en)
|
2022-12-01 |
2025-07-01 |
Pfizer |
Pneumococcal conjugate vaccine preparations
|
|
EP4661911A1
(en)
|
2023-02-10 |
2025-12-17 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
KR20250163977A
(ko)
|
2023-03-30 |
2025-11-21 |
화이자 인코포레이티드 |
접합된 피막 사카라이드 항원을 포함하는 면역원성 조성물 및 그의 용도
|
|
EP4694921A1
(en)
|
2023-04-14 |
2026-02-18 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
EP4701656A1
(en)
|
2023-04-24 |
2026-03-04 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
WO2024241172A2
(en)
|
2023-05-19 |
2024-11-28 |
Glaxosmithkline Biologicals Sa |
Methods for eliciting an immune response to respiratory syncycial virus and streptococcus pneumoniae infection
|
|
WO2025057078A1
(en)
|
2023-09-14 |
2025-03-20 |
Pfizer Inc. |
Adjuvanted immunogenic compositions comprising conjugated pneumococcal capsular saccharide antigens and uses thereof
|
|
WO2025133971A1
(en)
|
2023-12-23 |
2025-06-26 |
Pfizer Inc. |
Improved methods for producing bacterial capsular saccharide glycoconjugates
|
|
WO2025186705A2
(en)
|
2024-03-06 |
2025-09-12 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
|
TW202602467A
(zh)
|
2024-03-11 |
2026-01-16 |
美商輝瑞股份有限公司 |
包含經共軛之大腸桿菌糖的免疫原性組成物及其用途
|
|
WO2025219908A2
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Media and fermentation methods for polysaccharide production in bacterial cell culture
|
|
WO2025219904A1
(en)
|
2024-04-19 |
2025-10-23 |
Pfizer Inc. |
Improved methods for producing glycoconjugates by reductive amination in aprotic solvent
|